{"id":"coriogonadotropin-alfa","safety":{"commonSideEffects":[{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain/discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug mimics the natural hormone hCG, which is produced after embryo implantation to maintain the corpus luteum and ensure adequate progesterone secretion during early pregnancy. By providing exogenous hCG support during the luteal phase following ovarian stimulation and embryo transfer, it enhances endometrial receptivity and reduces miscarriage risk in fertility treatments. The recombinant formulation offers a consistent, pure alternative to urinary-derived hCG.","oneSentence":"Coriogonadotropin alfa is a recombinant human chorionic gonadotropin (hCG) analog that stimulates the corpus luteum to produce progesterone for luteal phase support in assisted reproductive technology.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:48.515Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Luteal phase support in assisted reproductive technology (ART) / in vitro fertilization (IVF)"}]},"trialDetails":[{"nctId":"NCT07340827","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)","status":"RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2026-02-05","conditions":"Infertility","enrollment":333}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13094,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["r-hCG"],"phase":"phase_3","status":"active","brandName":"Coriogonadotropin alfa","genericName":"Coriogonadotropin alfa","companyName":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","companyId":"merck-healthcare-kgaa-darmstadt-germany-an-affiliate-of-merck-kgaa-darmstadt-ger","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Coriogonadotropin alfa is a recombinant human chorionic gonadotropin (hCG) analog that stimulates the corpus luteum to produce progesterone for luteal phase support in assisted reproductive technology. Used for Luteal phase support in assisted reproductive technology (ART) / in vitro fertilization (IVF).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}